One-Time Injectable Drug Enters Final Stage Clinical Trials A new drug developed by Nymox Pharmaceutical may offer doctors a breakthrough in the treatment of a common affliction of men, an enlarged prostate or BPH (benign prostatic hyperplasia). The drug, a novel protein called NX-1207, is entering Phase 3 clinical trials, the last stage before applying for FDA approval. If approved, the drug could offer new hope for the millions of men suffering from BPH. NX-1207 takes a new ...